Title:
GPC3-TARGETED CAR NK CELL
Document Type and Number:
WIPO Patent Application WO/2019/024933
Kind Code:
A1
Abstract:
Provided is a chimeric antigen receptor NK cell expressing specific recognition for GPC3 and preparation method therefor, as well as a use of the cell in prevention and/or treatment of cancers, especially a GPC3-expression cancer. Also provided is a use of the NK cell as a targeting cell therapeutic agent and/or in adoptive immunotherapy of cancers.
Inventors:
LI ZONGHAI (CN)
YU MIN (CN)
GAO HUIPING (CN)
YU MIN (CN)
GAO HUIPING (CN)
Application Number:
PCT/CN2018/098623
Publication Date:
February 07, 2019
Filing Date:
August 03, 2018
Export Citation:
Assignee:
CARSGEN THERAPEUTICS CO LTD (CN)
SHANGHAI CANCER INST (CN)
SHANGHAI CANCER INST (CN)
International Classes:
C12N5/10; C07K16/28
Foreign References:
| CN104140974A | 2014-11-12 |
Other References:
LI, KEYU ET AL.: "Chimeric Antigen Receptor-Engineered T Cells for Liver Cancers, Progress and Obstacles", TUMOR BIOLOGY, vol. 39, no. 3, 28 March 2017 (2017-03-28), pages 1 - 8, XP055571345, ISSN: 1423-0380
YU , MIN ET AL.: "Development of GPC3-Specific Chimeric Antigen Receptor-Engineered Natural Killer Cells for the Treatment of Hepatocellular Carcinoma", MOLECULAR THERAPY, vol. 26, no. 2, 7 February 2018 (2018-02-07), pages 366 - 378, XP055565104, ISSN: 1525-0016
YU , MIN ET AL.: "Development of GPC3-Specific Chimeric Antigen Receptor-Engineered Natural Killer Cells for the Treatment of Hepatocellular Carcinoma", MOLECULAR THERAPY, vol. 26, no. 2, 7 February 2018 (2018-02-07), pages 366 - 378, XP055565104, ISSN: 1525-0016
Attorney, Agent or Firm:
XU & PARTNERS, LLC. (CN)
Download PDF:
Previous Patent: MULTI-TID A-MPDU TRANSMISSION
Next Patent: PROXY CALL SESSION CONTROL FUNCTION FAULT RECOVERING METHOD, APPARATUS AND SYSTEM
Next Patent: PROXY CALL SESSION CONTROL FUNCTION FAULT RECOVERING METHOD, APPARATUS AND SYSTEM